Pfizer is targeting late-November to apply for emergency use approval of its Covid-19 vaccine in the U.S., Reuters reports.

Pfizer is developing its vaccine candidate with Germany’s BioNTech and estimated a key safety milestone would be achieved in the third week of November.

That would be the first emergency use approval request for a Covid-19 vaccine, though several coronavirus treatments have already gone through the process. President Donald Trump has repeatedly touted a November timeline for a vaccine while providing few specifics. 

Source: CNBC

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.